{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:48:01Z","timestamp":1792140481477,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AFM-Telethon","award":["24401"],"award-info":[{"award-number":["24401"]}]},{"name":"AFM-Telethon","award":["24401"],"award-info":[{"award-number":["24401"]}]},{"name":"Italian Telethon Foundation","award":["GGP16203"],"award-info":[{"award-number":["GGP16203"]}]},{"name":"Italian Telethon Foundation","award":["GGP16203"],"award-info":[{"award-number":["GGP16203"]}]},{"name":"National Recovery and Resilience Plan","award":["Mission M4C2I1.3, PRR.AP015.118"],"award-info":[{"award-number":["Mission M4C2I1.3, PRR.AP015.118"]}]},{"name":"Ministry of University and Research","award":["Department of Excellence"],"award-info":[{"award-number":["Department of Excellence"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Spinal Muscular Atrophy (SMA) is a neurodegenerative disorder affecting lower motor neurons (MNs) and leading to muscle atrophy, due to mutation of the\n                    <jats:italic>SMN1<\/jats:italic>\n                    gene, which encodes SMN protein. Experimental studies also demonstrated the upper MN impairment. The available approved drugs for SMA increase the SMN protein production. Although effective, outcomes are dependent upon treatment timing and disease severity. Drug repositioning may represent a valid strategy to identify new treatments by repurposing FDA\/EMA-approved drugs that, combined with the available ones, could delay neurodegeneration. To this aim, for the first time we used primary cortical neurons derived from the SMN\u03947 mice as defective in vitro disease model, to preliminary assess drug efficacy on neuronal survival and morphology. Under basal conditions, SMA cortical neurons showed significantly reduced vitality and altered morphology compared to WT neurons. All the parameters were rescued after treatment with known compounds (Valproic Acid, 4-aminopyridine and N-acetylcysteine), already tested in either preclinical or clinical context for SMA. We then investigated for the first time in SMA pathology the efficacy of 10H-phenothiazine (10H-PTZ), known to exert neuroprotection and to target altered mechanisms in Parkinson\u2019s and Alzheimer\u2019s disease. Its administration to SMA cortical neurons induced significant protective effects on both neuronal survival and morphology that were further confirmed in vivo, in a\n                    <jats:italic>C. elegans<\/jats:italic>\n                    SMA model. Overall, our results provide valuable insights, both in vitro and in vivo, into the potential of 10\u00a0H-PTZ repurposing for SMA, although additional functional studies will be required.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-28547-9","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:54:10Z","timestamp":1765900450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["10H-phenothiazine exerts beneficial effects in spinal muscular atrophy in vitro and in vivo models"],"prefix":"10.1038","volume":"15","author":[{"given":"Daniela Maria","family":"Ras\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Stanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Santonicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Mazzarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Camera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Matino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Zampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Boido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Di Schiavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vercelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"28547_CR1","doi-asserted-by":"publisher","first-page":"e82654","DOI":"10.1371\/journal.pone.0082654","volume":"8","author":"P d\u2019Errico","year":"2013","unstructured":"d\u2019Errico, P. et al. Selective vulnerability of spinal and cortical motor neuron subpopulations in delta7 SMA mice. PLoS One. 8, e82654 (2013).","journal-title":"PLoS One"},{"key":"28547_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155\u2013165 (1995).","journal-title":"Cell"},{"key":"28547_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","volume":"10","author":"AHM Burghes","year":"2009","unstructured":"Burghes, A. H. M. & Beattie, C. E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci. 10, 597\u2013609 (2009).","journal-title":"Nat. Rev. Neurosci."},{"key":"28547_CR4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus Sham control in Infantile-Onset spinal muscular atrophy. N Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N Engl. J. Med."},{"key":"28547_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Single-Dose Gene-Replacement therapy for spinal muscular atrophy. N Engl. J. Med. 377, 1713\u20131722 (2017).","journal-title":"N Engl. J. Med."},{"key":"28547_CR6","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1212\/WNL.94.15_supplement.1260","volume":"94","author":"E Mercuri","year":"2020","unstructured":"Mercuri, E. et al. SUNFISH part 2: efficacy and safety of Risdiplam (RG7916) in patients with type 2 or Non-Ambulant type 3 spinal muscular atrophy (SMA) (1260). Neurology 94, 1260 (2020).","journal-title":"Neurology"},{"key":"28547_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molmed.2024.12.006","volume":"31","author":"F Moultrie","year":"2025","unstructured":"Moultrie, F., Chiverton, L., Hatami, I., Lilien, C. & Servais, L. Pushing the boundaries: future directions in the management of spinal muscular atrophy. Trends Mol. Med. 31, 307\u2013318 (2025).","journal-title":"Trends Mol. Med."},{"key":"28547_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41434-022-00349-y","volume":"30","author":"A Reilly","year":"2023","unstructured":"Reilly, A., Chehade, L., Kothary, R. & Curing, S. M. A. Are we there yet? Gene Ther. 30, 8\u201317 (2023).","journal-title":"Gene Ther."},{"key":"28547_CR9","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","volume":"24","author":"M Van Alstyne","year":"2021","unstructured":"Van Alstyne, M. et al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat. Neurosci. 24, 930\u2013940 (2021).","journal-title":"Nat. Neurosci."},{"key":"28547_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10571-024-01508-y","volume":"44","author":"M Barbo","year":"2024","unstructured":"Barbo, M. et al. Genetic variability in oxidative Stress, Inflammatory, and neurodevelopmental pathways: impact on the susceptibility and course of spinal muscular atrophy. Cell. Mol. Neurobiol. 44, 71 (2024).","journal-title":"Cell. Mol. Neurobiol."},{"key":"28547_CR11","doi-asserted-by":"crossref","unstructured":"Edinoff, A. N. et al. Phenothiazines and their evolving roles in clinical practice: A narrative review. Health Psychol. Research 10, (2022).","DOI":"10.52965\/001c.38930"},{"key":"28547_CR12","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2024.0096","author":"W Zhang","year":"2025","unstructured":"Zhang, W. et al. Phenothiazine confers neuroprotection via Dpp2\/7 in high altitude traumatic brain injury mouse model. High. Alt Med. Biol. https:\/\/doi.org\/10.1089\/ham.2024.0096 (2025).","journal-title":"High. Alt Med. Biol."},{"key":"28547_CR13","doi-asserted-by":"publisher","first-page":"113419","DOI":"10.1016\/j.ejmech.2021.113419","volume":"219","author":"KC Hsu","year":"2021","unstructured":"Hsu, K. C. et al. Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors. Eur. J. Med. Chem. 219, 113419 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"28547_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.drudis.2011.01.001","volume":"16","author":"MJ Ohlow","year":"2011","unstructured":"Ohlow, M. J. & Moosmann, B. Phenothiazine: the seven lives of pharmacology\u2019s first lead structure. Drug Discovery Today. 16, 119\u2013131 (2011).","journal-title":"Drug Discovery Today"},{"key":"28547_CR15","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3390\/antiox11091631","volume":"11","author":"A Carocci","year":"2022","unstructured":"Carocci, A. et al. Novel Phenothiazine\/Donepezil-like hybrids endowed with antioxidant activity for a Multi-Target approach to the therapy of alzheimer\u2019s disease. Antioxid. (Basel). 11, 1631 (2022).","journal-title":"Antioxid. (Basel)"},{"key":"28547_CR16","doi-asserted-by":"publisher","first-page":"113821","DOI":"10.1016\/j.ejmech.2021.113821","volume":"225","author":"XX Wang","year":"2021","unstructured":"Wang, X. X. et al. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against alzheimer\u2019s disease. Eur. J. Med. Chem. 225, 113821 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"28547_CR17","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1111\/cbdd.13572","volume":"94","author":"RG Keynes","year":"2019","unstructured":"Keynes, R. G. et al. N10-carbonyl-substituted phenothiazines inhibiting lipid peroxidation and associated nitric oxide consumption powerfully protect brain tissue against oxidative stress. Chem. Biol. Drug Des. 94, 1680\u20131693 (2019).","journal-title":"Chem. Biol. Drug Des."},{"key":"28547_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40263-019-00606-6","volume":"33","author":"A Elshafay","year":"2019","unstructured":"Elshafay, A. et al. Efficacy and safety of valproic acid for spinal muscular atrophy: A systematic review and Meta-Analysis. CNS Drugs. 33, 239\u2013250 (2019).","journal-title":"CNS Drugs"},{"key":"28547_CR19","doi-asserted-by":"crossref","unstructured":"Marasco, L. E. et al. Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy. Cell 185, (2022). 2057\u20132070.e15.","DOI":"10.1016\/j.cell.2022.04.031"},{"key":"28547_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2020.07.007","volume":"30","author":"CA Chiriboga","year":"2020","unstructured":"Chiriboga, C. A. et al. Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients. Neuromuscul. Disord. 30, 693\u2013700 (2020).","journal-title":"Neuromuscul. Disord."},{"key":"28547_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cell.2012.09.011","volume":"151","author":"WL Imlach","year":"2012","unstructured":"Imlach, W. L. et al. SMN is required for sensory-motor circuit function in drosophila. Cell 151, 427\u2013439 (2012).","journal-title":"Cell"},{"key":"28547_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1523\/JNEUROSCI.2142-20.2020","volume":"41","author":"CM Simon","year":"2021","unstructured":"Simon, C. M. et al. Chronic Pharmacological increase of neuronal activity improves Sensory-Motor dysfunction in spinal muscular atrophy mice. J. Neurosci. 41, 376\u2013389 (2021).","journal-title":"J. Neurosci."},{"key":"28547_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/cr.2012.166","volume":"23","author":"ZB Wang","year":"2013","unstructured":"Wang, Z. B., Zhang, X. & Li, X. J. Recapitulation of spinal motor neuron-specific disease phenotypes in a human cell model of spinal muscular atrophy. Cell. Res. 23, 378\u2013393 (2013).","journal-title":"Cell. Res."},{"key":"28547_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1242\/dmm.021766","volume":"9","author":"CC Xu","year":"2016","unstructured":"Xu, C. C., Denton, K. R., Wang, Z. B., Zhang, X. & Li, X. J. Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy. Dis. Models Mech. 9, 39\u201349 (2016).","journal-title":"Dis. Models Mech."},{"key":"28547_CR25","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1096\/fj.15-278739","volume":"30","author":"S Stanga","year":"2016","unstructured":"Stanga, S. et al. APP-dependent glial cell line-derived neurotrophic factor gene expression drives neuromuscular junction formation. FASEB J. 30, 1696\u20131711 (2016).","journal-title":"FASEB J."},{"key":"28547_CR26","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1038\/s41467-023-42372-6","volume":"14","author":"C Hoffmann","year":"2023","unstructured":"Hoffmann, C. et al. Synapsin condensation controls synaptic vesicle sequestering and dynamics. Nat. Commun. 14, 6730 (2023).","journal-title":"Nat. Commun."},{"key":"28547_CR27","first-page":"2564","volume":"25","author":"I Gallotta","year":"2016","unstructured":"Gallotta, I. et al. Neuron-specific knock-down of SMN1 causes neuron degeneration and death through an apoptotic mechanism. Hum. Mol. Genet. 25, 2564\u20132577 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"28547_CR28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1242\/dmm.030148","volume":"10","author":"M Bowerman","year":"2017","unstructured":"Bowerman, M. et al. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis. Model. Mech. 10, 943\u2013954 (2017).","journal-title":"Dis. Model. Mech."},{"key":"28547_CR29","doi-asserted-by":"crossref","unstructured":"Pinzi, L., Bisi, N. & Rastelli, G. How drug repurposing can advance drug discovery: challenges and opportunities. Front Drug Discov 4, (2024).","DOI":"10.3389\/fddsv.2024.1460100"},{"key":"28547_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov"},{"key":"28547_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10571-024-01511-3","volume":"44","author":"S Basak","year":"2024","unstructured":"Basak, S., Biswas, N., Gill, J. & Ashili, S. Spinal muscular atrophy: current medications and Re-purposed drugs. Cell. Mol. Neurobiol. 44, 75 (2024).","journal-title":"Cell. Mol. Neurobiol."},{"key":"28547_CR32","doi-asserted-by":"crossref","unstructured":"Menduti, G., Ras\u00e0, D. M., Stanga, S. & Boido, M. Drug screening and drug repositioning as promising therapeutic approaches for spinal muscular atrophy treatment. Front Pharmacol 11, (2020).","DOI":"10.3389\/fphar.2020.592234"},{"key":"28547_CR33","doi-asserted-by":"publisher","first-page":"586108","DOI":"10.3389\/fnins.2020.586108","volume":"14","author":"S Contino","year":"2020","unstructured":"Contino, S. et al. Presenilin-Deficient neurons and astrocytes display normal mitochondrial phenotypes. Front. Neurosci. 14, 586108 (2020).","journal-title":"Front. Neurosci."},{"key":"28547_CR34","doi-asserted-by":"crossref","unstructured":"Opsomer, R. et al. Amyloid Precursor Protein (APP) Controls the Expression of the Transcriptional Activator Neuronal PAS Domain Protein 4 (NPAS4) and Synaptic GABA Release. eNeuro 7, (2020).","DOI":"10.1523\/ENEURO.0322-19.2020"},{"key":"28547_CR35","doi-asserted-by":"publisher","first-page":"e200193","DOI":"10.1212\/NXG.0000000000200193","volume":"10","author":"E Groulx-Boivin","year":"2024","unstructured":"Groulx-Boivin, E. et al. Macrostructural brain abnormalities in spinal muscular atrophy. Neurol. Genet. 10, e200193 (2024).","journal-title":"Neurol. Genet."},{"key":"28547_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","volume":"19","author":"G Hamilton","year":"2013","unstructured":"Hamilton, G. & Gillingwater, T. H. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol. Med. 19, 40\u201350 (2013).","journal-title":"Trends Mol. Med."},{"key":"28547_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","volume":"109","author":"CJJ Yeo","year":"2020","unstructured":"Yeo, C. J. J. & Darras, B. T. Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr. Neurol. 109, 12\u201319 (2020).","journal-title":"Pediatr. Neurol."},{"key":"28547_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/joa.12083","volume":"224","author":"M Shababi","year":"2014","unstructured":"Shababi, M., Lorson, C. L. & Rudnik-Sch\u00f6neborn, S. S. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J. Anat. 224, 15\u201328 (2014).","journal-title":"J. Anat."},{"key":"28547_CR39","doi-asserted-by":"publisher","first-page":"101164","DOI":"10.1016\/j.redox.2019.101164","volume":"24","author":"V Tapias","year":"2019","unstructured":"Tapias, V., McCoy, J. L. & Greenamyre, J. T. Phenothiazine normalizes the NADH\/NAD\u2009+\u2009ratio, maintains mitochondrial integrity and protects the nigrostriatal dopamine system in a chronic rotenone model of parkinson\u2019s disease. Redox Biol. 24, 101164 (2019).","journal-title":"Redox Biol."},{"key":"28547_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.semcdb.2011.07.003","volume":"22","author":"M Bykhovskaia","year":"2011","unstructured":"Bykhovskaia, M. Synapsin regulation of vesicle organization and functional pools. Semin. Cell Dev. Biol. 22, 387\u2013392 (2011).","journal-title":"Semin. Cell Dev. Biol."},{"key":"28547_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0896-6273(03)00151-X","volume":"38","author":"P Chi","year":"2003","unstructured":"Chi, P., Greengard, P. & Ryan, T. A. Synaptic vesicle mobilization is regulated by distinct synapsin I phosphorylation pathways at different frequencies. Neuron 38, 69\u201378 (2003).","journal-title":"Neuron"},{"key":"28547_CR42","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1126\/science.8430330","volume":"259","author":"P Greengard","year":"1993","unstructured":"Greengard, P., Valtorta, F., Czernik, A. J. & Benfenati, F. Synaptic vesicle phosphoproteins and regulation of synaptic function. Science 259, 780\u2013785 (1993).","journal-title":"Science"},{"key":"28547_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neubiorev.2021.08.011","volume":"130","author":"F Longhena","year":"2021","unstructured":"Longhena, F. et al. An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders. Neurosci. Biobehav Rev. 130, 33\u201360 (2021).","journal-title":"Neurosci. Biobehav Rev."},{"key":"28547_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-2106-z","volume":"10","author":"A Rocchi","year":"2019","unstructured":"Rocchi, A. et al. Autoantibodies to synapsin I sequestrate synapsin I and alter synaptic function. Cell. Death Dis. 10, 1\u201316 (2019).","journal-title":"Cell. Death Dis."},{"issue":"dmm046391","key":"28547_CR45","doi-asserted-by":"publisher","first-page":"dmm046391","DOI":"10.1242\/dmm.046391","volume":"14","author":"A Niceforo","year":"2021","unstructured":"Niceforo, A. et al. Altered cytoskeletal arrangement in induced pluripotent stem cells (iPSCs) and motor neurons from patients with riboflavin transporter deficiency. Dis. Model. Mech. 14 (dmm046391), dmm046391 (2021).","journal-title":"Dis. Model. Mech."},{"key":"28547_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/hmg\/ddn320","volume":"18","author":"M Briese","year":"2009","unstructured":"Briese, M. et al. Deletion of smn-1, the caenorhabditis elegans ortholog of the spinal muscular atrophy gene, results in locomotor dysfunction and reduced lifespan. Hum. Mol. Genet. 18, 97\u2013104 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"28547_CR47","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/hmg\/8.12.2133","volume":"8","author":"I Miguel-Aliaga","year":"1999","unstructured":"Miguel-Aliaga, I. et al. The caenorhabditis elegans orthologue of the human gene responsible for spinal muscular atrophy is a maternal product critical for germline maturation and embryonic viability. Hum. Mol. Genet. 8, 2133\u20132143 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"28547_CR48","doi-asserted-by":"publisher","first-page":"iyae050","DOI":"10.1093\/genetics\/iyae050","volume":"227","author":"PW Sternberg","year":"2024","unstructured":"Sternberg, P. W. et al. WormBase 2024: status and transitioning to alliance infrastructure. Genetics 227, iyae050 (2024).","journal-title":"Genetics"},{"key":"28547_CR49","doi-asserted-by":"publisher","first-page":"e1001172","DOI":"10.1371\/journal.pgen.1001172","volume":"6","author":"M Dimitriadi","year":"2010","unstructured":"Dimitriadi, M. et al. Conserved genes act as modifiers of invertebrate SMN loss of function defects. PLoS Genet. 6, e1001172 (2010).","journal-title":"PLoS Genet."},{"key":"28547_CR50","doi-asserted-by":"publisher","first-page":"110330","DOI":"10.1016\/j.celrep.2022.110330","volume":"38","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Escape steering by cholecystokinin peptidergic signaling. Cell. Rep. 38, 110330 (2022).","journal-title":"Cell. Rep."},{"key":"28547_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nbd.2017.05.005","volume":"105","author":"ML Di Giorgio","year":"2017","unstructured":"Di Giorgio, M. L. et al. WDR79\/TCAB1 plays a conserved role in the control of locomotion and ameliorates phenotypic defects in SMA models. Neurobiol. Dis. 105, 42\u201350 (2017).","journal-title":"Neurobiol. Dis."},{"key":"28547_CR52","doi-asserted-by":"crossref","unstructured":"Hensel, N. et al. Impairment of the neurotrophic signaling hub B-Raf contributes to motoneuron degeneration in spinal muscular atrophy. Proceedings of the National Academy of Sciences 118, e2007785118 (2021).","DOI":"10.1073\/pnas.2007785118"},{"key":"28547_CR53","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.3390\/cells9112405","volume":"9","author":"S Rademacher","year":"2020","unstructured":"Rademacher, S. et al. A single amino acid residue regulates PTEN-Binding and stability of the spinal muscular atrophy protein SMN. Cells 9, 2405 (2020).","journal-title":"Cells"},{"key":"28547_CR54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1039\/C8IB00091C","volume":"10","author":"C de C\u00e1ceres","year":"2018","unstructured":"de C\u00e1ceres, C. Automated screening of C. elegans neurodegeneration mutants enabled by microfluidics and image analysis algorithms. Integr. Biology. 10, 539\u2013548 (2018).","journal-title":"Integr. Biology"},{"key":"28547_CR55","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/brain\/awy330","volume":"142","author":"F Rizzo","year":"2019","unstructured":"Rizzo, F. et al. Key role of SMN\/SYNCRIP and RNA-Motif 7 in spinal muscular atrophy: RNA-Seq and motif analysis of human motor neurons. Brain 142, 276\u2013294 (2019).","journal-title":"Brain"},{"key":"28547_CR56","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/fsn3.1078","volume":"7","author":"N Mazzarella","year":"2019","unstructured":"Mazzarella, N. et al. Green Kiwifruit extracts protect motor neurons from death in a spinal muscular atrophy model in caenorhabditis elegans. Food Sci. Nutr. 7, 2327\u20132335 (2019).","journal-title":"Food Sci. Nutr."},{"key":"28547_CR57","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/j.bbadis.2013.08.005","volume":"1832","author":"J Seo","year":"2013","unstructured":"Seo, J., Howell, M. D., Singh, N. N. & Singh, R. N. Spinal muscular atrophy: an update on therapeutic progress. Biochim. Et Biophys. Acta (BBA) - Mol. Basis Disease. 1832, 2180\u20132190 (2013).","journal-title":"Biochim. Et Biophys. Acta (BBA) - Mol. Basis Disease"},{"key":"28547_CR58","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/hmg\/ddi078","volume":"14","author":"TT Le","year":"2005","unstructured":"Le, T. T. et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845\u2013857 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"28547_CR59","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jep.2015.01.028","volume":"163","author":"S Hage","year":"2015","unstructured":"Hage, S. et al. Characterization of pterocarpus Erinaceus Kino extract and its gamma-secretase inhibitory properties. J. Ethnopharmacol. 163, 192\u2013202 (2015).","journal-title":"J. Ethnopharmacol."},{"key":"28547_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/genetics\/77.1.71","volume":"77","author":"S Brenner","year":"1974","unstructured":"Brenner, S. The genetics of caenorhabditis elegans. Genetics 77, 71\u201394 (1974).","journal-title":"Genetics"},{"key":"28547_CR61","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/39908","volume":"389","author":"SL McIntire","year":"1997","unstructured":"McIntire, S. L., Reimer, R. J., Schuske, K., Edwards, R. H. & Jorgensen, E. M. Identification and characterization of the vesicular GABA transporter. Nature 389, 870\u2013876 (1997).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28547-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28547-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28547-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:03:22Z","timestamp":1777406602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28547-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["28547"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-28547-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45757"}}